<p>Geode Capital Management LLC 在最近向证券交易委员会的披露中表示，在第二季度增持了 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 免费报告) 的股份，增幅为 1.3%。该公司在本季度额外购买了 26,365 股后，持有 2,049,350 股该公司的股票。Geode Capital Management LLC 在最近一个季度末持有 Syndax Pharmaceuticals 约 2.38% 的股份，价值 19,195,000 美元。</p>
<p>获取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
<p>其他机构投资者最近也调整了对该公司的持股。Universal Beteiligungs und Servicegesellschaft mbH 在第一季度新购入了 Syndax Pharmaceuticals 的股份，价值 179,000 美元。XTX Topco Ltd 在第一季度购买了 Syndax Pharmaceuticals 的新头寸，价值 783,000 美元。德意志银行在第一季度将其在 Syndax Pharmaceuticals 的持股增加了 127.7%。德意志银行目前持有 204,732 股该公司的股票，价值 2,516,000 美元，此前在上个季度额外购入了 114,828 股。Invesco Ltd. 在第一季度将其在 Syndax Pharmaceuticals 的持股增加了 49.7%。Invesco Ltd. 目前持有 76,848 股该公司的股票，价值 944,000 美元，此前在此期间额外购入了 25,524 股。最后，Aigen Investment Management LP 在第一季度新购入了价值约 297,000 美元的 Syndax Pharmaceuticals 的股份。</p>
<h2>Syndax Pharmaceuticals 的内部活动</h2>
<p>在其他消息中，首席执行官 Michael A. Metzger 于 9 月 8 日星期一出售了 157,307 股 Syndax Pharmaceuticals 的股票。该股票以平均价格 16.41 美元出售，总交易额为 2,581,407.87 美元。出售后，首席执行官直接持有该公司 298,661 股股票，价值约 4,901,027.01 美元。此次交易使其持股减少了 34.50%。该出售在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。内部人士持有该公司 4.10% 的股票。</p>
<h2>Syndax Pharmaceuticals 的价格表现</h2>
<p>NASDAQ:SNDX 的股票在星期一开盘价为 20.12 美元。该公司的市值为 17.5 亿美元，市盈率为 -5.17，贝塔值为 0.73。该公司的流动比率为 4.71，速动比率为 4.55，债务与股本比率为 2.06。Syndax Pharmaceuticals, Inc. 的 1 年最低价为 8.58 美元，1 年最高价为 20.20 美元。该公司的 50 日移动平均线为 15.85 美元，200 日移动平均线为 13.26 美元。</p>
<p>Syndax Pharmaceuticals (NASDAQ:SNDX - 获取免费报告) 最近于 11 月 3 日发布了其财报。该公司报告本季度每股收益为（0.70）美元，超过了市场共识预期的（0.74）美元，超出幅度为 0.04 美元。Syndax Pharmaceuticals 的股本回报率为 -130.47%，净利润率为 -428.48%。该公司本季度的收入为 4587 万美元，而分析师预期为 4908 万美元。去年同期，该公司每股收益为（0.98）美元。与去年同期相比，Syndax Pharmaceuticals 的季度收入增长了 266.4%。卖方分析师预测 Syndax Pharmaceuticals, Inc. 本年度每股收益将为 -3.72 美元。</p>
<h2>分析师评级升级与降级</h2>
<p>几家研究机构最近对 SNDX 进行了评估。Weiss Ratings 在 11 月 25 日的研究报告中重新发布了对 Syndax Pharmaceuticals 的 &#34;卖出（d-）&#34; 评级。B. Riley 在 8 月 6 日的研究报告中将 Syndax Pharmaceuticals 的评级提升至 &#34;强力买入&#34;。巴克莱在 11 月 24 日的研究报告中将 Syndax Pharmaceuticals 的目标价从 22.00 美元提高至 35.00 美元，并给予该公司 &#34;增持&#34; 评级。花旗集团在 8 月 5 日的研究报告中将 Syndax Pharmaceuticals 的目标价从 46.00 美元提高至 51.00 美元，并给予该股票 &#34;买入&#34; 评级。最后，高盛集团在 9 月 5 日的研究报告中将 Syndax Pharmaceuticals 的目标价从 20.00 美元提高至 24.00 美元，并给予该公司 &#34;买入&#34; 评级。一位分析师对该股票给予了强力买入评级，九位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 37.20 美元。</p>
<p><strong>阅读我们最新的 SNDX 股票报告</strong></p>
<h2>关于 Syndax Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Syndax Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，开发用于癌症治疗的疗法。其主要产品候选药物包括 revumenib，一种强效、选择性的小分子抑制剂，针对 KMT2A 重排的急性白血病和实体肿瘤的 menin-MLL 结合相互作用；以及 SNDX-6352 或 axatilimab，一种单克隆抗体，阻断集落刺激因子 1（CSF-1）受体，用于治疗慢性移植物抗宿主病（cGVHD）和特发性肺纤维化（IPF）患者。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Syndax Pharmaceuticals</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>担心通货膨胀？这三只 ETF 提供真正的保护</li>
<li>最佳航空航天股票投资</li>
<li>英特尔的黑色星期五突破：苹果传闻推动假日反弹</li>
<li>为什么理解期权交易量对成功的期权交易至关重要</li>
<li>Klarna 的加密计划：解决其盈利问题的计划</li>
</ul>
<p><strong>想看看其他对 SNDX 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Syndax Pharmaceuticals 吗？</h2>
<p>在考虑 Syndax Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Syndax Pharmaceuticals 并不在名单上。</p>
<p>虽然 Syndax Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Syndax制药

<p>Geode Capital Management LLC 在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 1.3%，目前持有 2,049,350 股，价值 1920 万美元。其他机构投资者也调整了他们的持股。Syndax 的首席执行官出售了部分股份，公司报告第三季度收入同比增长 266.4%。分析师对该股票给予了 “适度买入” 的共识评级，目标价格为 37.20 美元</p>

<p>Geode Capital Management LLC boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 1.3% in the second quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 2,049,350 shares of the company's stock after purchasing an additional 26,365 shares during the quarter. Geode Capital Management LLC owned about 2.38% of Syndax Pharmaceuticals worth $19,195,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Geode Capital Management LLC 在最近向证券交易委员会的披露中表示，在第二季度增持了 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 免费报告) 的股份，增幅为 1.3%。该公司在本季度额外购买了 26,365 股后，持有 2,049,350 股该公司的股票。Geode Capital Management LLC 在最近一个季度末持有 Syndax Pharmaceuticals 约 2.38% 的股份，价值 19,195,000 美元。</p>
</div><p>Get <strong>Syndax Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
</div><p>Other institutional investors also recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Syndax Pharmaceuticals in the first quarter worth $179,000. XTX Topco Ltd bought a new position in Syndax Pharmaceuticals in the 1st quarter worth $783,000. Deutsche Bank AG lifted its position in Syndax Pharmaceuticals by 127.7% during the 1st quarter. Deutsche Bank AG now owns 204,732 shares of the company's stock worth $2,516,000 after acquiring an additional 114,828 shares during the last quarter. Invesco Ltd. boosted its holdings in Syndax Pharmaceuticals by 49.7% during the first quarter. Invesco Ltd. now owns 76,848 shares of the company's stock valued at $944,000 after acquiring an additional 25,524 shares during the period. Finally, Aigen Investment Management LP bought a new stake in Syndax Pharmaceuticals during the first quarter valued at about $297,000.</p>
<div class="lb-trans"><p>其他机构投资者最近也调整了对该公司的持股。Universal Beteiligungs und Servicegesellschaft mbH 在第一季度新购入了 Syndax Pharmaceuticals 的股份，价值 179,000 美元。XTX Topco Ltd 在第一季度购买了 Syndax Pharmaceuticals 的新头寸，价值 783,000 美元。德意志银行在第一季度将其在 Syndax Pharmaceuticals 的持股增加了 127.7%。德意志银行目前持有 204,732 股该公司的股票，价值 2,516,000 美元，此前在上个季度额外购入了 114,828 股。Invesco Ltd. 在第一季度将其在 Syndax Pharmaceuticals 的持股增加了 49.7%。Invesco Ltd. 目前持有 76,848 股该公司的股票，价值 944,000 美元，此前在此期间额外购入了 25,524 股。最后，Aigen Investment Management LP 在第一季度新购入了价值约 297,000 美元的 Syndax Pharmaceuticals 的股份。</p>
</div><h2>Insider Activity at Syndax Pharmaceuticals</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 的内部活动</h2>
</div><p>In other news, CEO Michael A. Metzger sold 157,307 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the sale, the chief executive officer directly owned 298,661 shares in the company, valued at approximately $4,901,027.01. The trade was a 34.50% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders own 4.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Michael A. Metzger 于 9 月 8 日星期一出售了 157,307 股 Syndax Pharmaceuticals 的股票。该股票以平均价格 16.41 美元出售，总交易额为 2,581,407.87 美元。出售后，首席执行官直接持有该公司 298,661 股股票，价值约 4,901,027.01 美元。此次交易使其持股减少了 34.50%。该出售在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。内部人士持有该公司 4.10% 的股票。</p>
</div><h2>Syndax Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 的价格表现</h2>
</div><p>Shares of NASDAQ:SNDX opened at $20.12 on Monday. The firm has a market capitalization of $1.75 billion, a PE ratio of -5.17 and a beta of 0.73. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.58 and a 1-year high of $20.20. The business's 50 day moving average is $15.85 and its 200-day moving average is $13.26.</p>
<div class="lb-trans"><p>NASDAQ:SNDX 的股票在星期一开盘价为 20.12 美元。该公司的市值为 17.5 亿美元，市盈率为 -5.17，贝塔值为 0.73。该公司的流动比率为 4.71，速动比率为 4.55，债务与股本比率为 2.06。Syndax Pharmaceuticals, Inc. 的 1 年最低价为 8.58 美元，1 年最高价为 20.20 美元。该公司的 50 日移动平均线为 15.85 美元，200 日移动平均线为 13.26 美元。</p>
</div><p>Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Monday, November 3rd. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.04. Syndax Pharmaceuticals had a negative return on equity of 130.47% and a negative net margin of 428.48%.The firm had revenue of $45.87 million during the quarter, compared to analysts' expectations of $49.08 million. During the same period last year, the business earned ($0.98) earnings per share. Syndax Pharmaceuticals's quarterly revenue was up 266.4% compared to the same quarter last year. Sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals (NASDAQ:SNDX - 获取免费报告) 最近于 11 月 3 日发布了其财报。该公司报告本季度每股收益为（0.70）美元，超过了市场共识预期的（0.74）美元，超出幅度为 0.04 美元。Syndax Pharmaceuticals 的股本回报率为 -130.47%，净利润率为 -428.48%。该公司本季度的收入为 4587 万美元，而分析师预期为 4908 万美元。去年同期，该公司每股收益为（0.98）美元。与去年同期相比，Syndax Pharmaceuticals 的季度收入增长了 266.4%。卖方分析师预测 Syndax Pharmaceuticals, Inc. 本年度每股收益将为 -3.72 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>Several research firms recently weighed in on SNDX. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Syndax Pharmaceuticals in a research report on Tuesday, November 25th. B. Riley raised Syndax Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Wednesday, August 6th. Barclays increased their price objective on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, November 24th. Citigroup raised their price objective on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, August 5th. Finally, The Goldman Sachs Group upped their target price on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $37.20.</p>
<div class="lb-trans"><p>几家研究机构最近对 SNDX 进行了评估。Weiss Ratings 在 11 月 25 日的研究报告中重新发布了对 Syndax Pharmaceuticals 的 &#34;卖出（d-）&#34; 评级。B. Riley 在 8 月 6 日的研究报告中将 Syndax Pharmaceuticals 的评级提升至 &#34;强力买入&#34;。巴克莱在 11 月 24 日的研究报告中将 Syndax Pharmaceuticals 的目标价从 22.00 美元提高至 35.00 美元，并给予该公司 &#34;增持&#34; 评级。花旗集团在 8 月 5 日的研究报告中将 Syndax Pharmaceuticals 的目标价从 46.00 美元提高至 51.00 美元，并给予该股票 &#34;买入&#34; 评级。最后，高盛集团在 9 月 5 日的研究报告中将 Syndax Pharmaceuticals 的目标价从 20.00 美元提高至 24.00 美元，并给予该公司 &#34;买入&#34; 评级。一位分析师对该股票给予了强力买入评级，九位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 37.20 美元。</p>
</div><p><strong>Read Our Latest Stock Report on SNDX</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 SNDX 股票报告</strong></p>
</div><h2>About Syndax Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Syndax Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，开发用于癌症治疗的疗法。其主要产品候选药物包括 revumenib，一种强效、选择性的小分子抑制剂，针对 KMT2A 重排的急性白血病和实体肿瘤的 menin-MLL 结合相互作用；以及 SNDX-6352 或 axatilimab，一种单克隆抗体，阻断集落刺激因子 1（CSF-1）受体，用于治疗慢性移植物抗宿主病（cGVHD）和特发性肺纤维化（IPF）患者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Syndax Pharmaceuticals</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Worried About Inflation? These 3 ETFs Offer Real Protection</li>
<li>Best Aerospace Stocks Investing</li>
<li>Intel’s Black Friday Breakout: Apple Rumors Fuel a Holiday Rally</li>
<li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li>
<li>Klarna's Crypto Play: A Plan to Fix Its Profit Problem</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Syndax Pharmaceuticals</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>担心通货膨胀？这三只 ETF 提供真正的保护</li>
<li>最佳航空航天股票投资</li>
<li>英特尔的黑色星期五突破：苹果传闻推动假日反弹</li>
<li>为什么理解期权交易量对成功的期权交易至关重要</li>
<li>Klarna 的加密计划：解决其盈利问题的计划</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding SNDX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 SNDX 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SNDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Syndax Pharmaceuticals 吗？</h2>
</div><p>Before you consider Syndax Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Syndax Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Syndax Pharmaceuticals 并不在名单上。</p>
</div><p>While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Syndax Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Geode Capital Management LLC 在 Syndax 制药公司$SNDX 中持有 1920 万美元的头寸